Cardiovascular Systems (CSI) has secured approval for its Diamondback 360 Coronary Orbital Atherectomy System (OAS) Micro Crown from the US Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labor and Welfare (MHLW).

FDA approval allows the device to be used to enable stent delivery in coronary artery disease (CAD) patients who are candidates for percutaneous transluminal coronary angioplasty (PTCA) or stenting related to de-novo, severely calcified coronary artery lesions.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Regulatory approval in Japan recognises the device as a frontline treatment for de-novo severely calcified lesions and to allow access to arteries for percutaneous coronary interventions (PCI). 

The atherectomy system is designed to pilot tight, calcific lesions and treat vessels of various sizes, as well as provide continuous blood flow during treatment.

"Patients with severely calcified coronary lesions are some of the most difficult to treat, leading to worse clinical and economic outcomes."

The diamond-coated tip enables instant access through tight, severely calcified lesions and treatment of up to 4mm vessels, while the sanding crown's increased mass facilitates lower rotational speeds.

CSI chairman, president and chief executive officer Scott Ward said: "We are committed to continued advancement of CSI’s proven OAS technology focused on severe coronary arterial calcium, which is an underserved problem in vascular medicine.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"Patients with severely calcified coronary lesions are some of the most difficult to treat, leading to worse clinical and economic outcomes.

"The ORBIT II and COAST studies demonstrated that orbital atherectomy technology is safe and effective in treating patients with severely calcified lesions."

The Harmonisation-By-Doing COAST trial was conducted in the US and Japan under the regulations of both governments.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact